Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) and Orchestra BioMed (NASDAQ:OBIO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.
Profitability
This table compares Contineum Therapeutics and Orchestra BioMed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Contineum Therapeutics | N/A | -27.09% | -25.64% |
| Orchestra BioMed | -166.96% | -157.46% | -60.18% |
Earnings and Valuation
This table compares Contineum Therapeutics and Orchestra BioMed”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Contineum Therapeutics | N/A | N/A | -$59.98 million | ($1.95) | -6.71 |
| Orchestra BioMed | $33.48 million | 6.85 | -$52.70 million | ($0.97) | -3.95 |
Orchestra BioMed has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and target prices for Contineum Therapeutics and Orchestra BioMed, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Contineum Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
| Orchestra BioMed | 1 | 1 | 5 | 0 | 2.57 |
Contineum Therapeutics presently has a consensus price target of $20.00, indicating a potential upside of 52.79%. Orchestra BioMed has a consensus price target of $13.60, indicating a potential upside of 255.09%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Contineum Therapeutics.
Risk and Volatility
Contineum Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.
Insider and Institutional Ownership
53.2% of Orchestra BioMed shares are owned by institutional investors. 11.3% of Contineum Therapeutics shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Orchestra BioMed beats Contineum Therapeutics on 8 of the 13 factors compared between the two stocks.
About Contineum Therapeutics
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
About Orchestra BioMed
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
